← All trials
NCT06382129
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2024
- Primary completion
- May 31, 2026
- Completion date
- May 31, 2026
- First posted
- Apr 24, 2024
- Last posted
- Sep 25, 2024
- Enrollment
- 604
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Baili Pharmaceutical GroupLead sponsor
- Chinese Academy of Medical SciencesOfficial
- Baili Pharmaceutical GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.